Reliable Establishment of Human Sarcoma Xenografts in the Nude Rat by Tinkey, Peggy T. et al.
Sarcoma (1999) 3, 129± 133
SHORT REPORT
Reliable establishment of human sarcoma xenografts in the nude rat
PEGGY T.TINKEY,
1 MIRA MILAS
2 & RAPHAEL E. POLLOCK
2
Departments of
1Veterinary Medicine and Surgery and
2Department of Surgical Oncology,The University of Texas M. D.
Anderson Cancer Center, 1515 Holcombe Blvd., Houston,TX 77030, USA
Key words: tumor xenograft, nude rat, sarcoma
Abstract
Purpose. The ability to establish consistent human tumor xenografts in experimental animals is a crucial part of preclinical
investigations.The goal of this study was to develop a method of establishing a human tumor xenograft in the leg of a nude
rat for evaluation of new surgical and molecular methods of treatments of human extremity sarcoma.
Methods and results. Initial attempts to produce sarcoma nodules by subcutaneous injection of a human leiomyosarcoma
tumor cell suspension (SKLMS-1) resulted in tumor nodule formation in only four of 10 sites (40%).The xenograft method
was modi® ed to include younger nude rats of a different source and substrain (HSD:rnu/rnu, 5± 9 weeks old), treated with
500 cGy whole-body irradiation, and the transplantation of tumor cells or small tumor fragments which had been embedded
in Matrigel.These changes improved the tumor take rate per site to 52/52 (100%).Tumor nodules demonstrated rapid and
progressive growth and histological features consistent with the original human sarcoma.
Discussion. Successful human leiomyosarcoma establishment in these nude rats permits the investigation of sarcoma
biology and treatment with surgical procedures for which a mouse model would be inadequate. In this study we identi® ed
modi® cations in technique which enhanced the xenografting of a leiomyosarcoma cell line in nude rats;these techniques may
increase tumor take rates for other tumor types as well.
Introduction
Human soft tissue sarcomas are a rare group of
heterogeneous tumors characterized by aggressive
local growth and hematogenous metastases, most
often to the lungs. Surgical resection, with or without
radiotherapy, is the cornerstone of the local treat-
ment of these sarcomas. Surgical methods that allow
limb preservation for patients who would otherwise
require amputation have also been developed.
1,2 An
example is isolated limb perfusion (ILP), which is
used to deliver high doses of chemotherapeutic agents
to an extremity tumor whose vascularity has been
temporarily isolated from the remainder of the body,
thereby preventing patient exposure to systemically
toxic drug concentrations.
2 Despite such advances,
the overall dismal prognosis for sarcoma patients and
the need to improve current treatment options neces-
sitate an active research effort and reliable preclinical
animal models.
3
Orthotopic xenografts of human tumors in nude
mice are an accepted model for in vivo biological and
preclinical studies;
4 however the small size of mice
limits their usefulness in many surgical applications.
The investigation of sarcoma tumor biology and
surgical techniques, such as ILP, in a larger labora-
tory animal therefore requires that a consistently
producible human tumor xenograft model be achiev-
able in such an animal.
We report here a method of generating human
sarcomas in the leg or ¯ ank of the nude rat that
results in excellent tumor take rates and consistent,
reliable growth patterns. The principles of xenograft
establishment described here for sarcomas may be
useful for research applications involving other types
of human tumors.
Methods
Animals
Female Rowett nude rats, 4± 6 weeks old, were
obtained from the National Cancer Institute (Freder-
ick Cancer Research Facility, Frederick, MD; strain
Cr:NIH-RNU) or from Harlan Sprague± Dawley
(Indianapolis, IN; strain HSD:rnu/rnu).The animals
were housed three per cage in sterilized rat microiso-
lator cages (Lab Products, Seaford, DE) containing
corncob bedding (Bed’o’Cob; Northeastern Products
Corp., Caspain, MO). The temperature was
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Animals were provided a 12-h light± dark cycle and
ad libitum autoclaved food (Harlan-Teklad, Madison,
WI) and water throughout the study. The experi-
ments were approved by the Institutional Animal Care
and Use Committee atThe University of Texas M.D.
Anderson Cancer Center. Animals received humane
care in accordance with the Animal Welfare Act and
the NIH Guide for the Care and Use of Laboratory
Animals.
Tumors
The human leiomyosarcoma SKLMS-1 was obtained
from the American Type Culture Collection (Rock-
ville, MD). SKLMS-1 is a well-characterized human
sarcoma cell line and contains a known p53 tumor
suppressor gene mutation.
5,6Tumor cells were either
maintained in cell culture or passaged in nude rat
subcutaneous tissue. Cells in culture were maintained
in DMEM/F12 medium containing 10% fetal bovine
serum (FBS, Life Technologies, Inc., Gaithersburg,
MD) in a 37Ê C humidi® ed incubator containing 5%
CO2 in air. Cells were subcultured 1:3 by trypsiniza-
tion upon reaching 90% con¯ uence. For experi-
ments, 90% con¯ uent cells were harvested by
trypsinization, washed in phosphate-buffered saline
(PBS), and assessed for viability by trypan blue dye
exclusion. The cells were then pelleted and resus-
pended in either PBS or Matrigel (Becton-Dickinson,
Bedford, MA). For passaged tumor, subcutaneously
growing SKLMS-1 nodules were resected aseptically
and trimmed of necrotic tissue.The remaining viable
tumor was rinsed in cold PBS, cut into 3 3 2-mm
slivers, immersed in Matrigel, and immediately
implanted into recipient rats. Matrigel is a solubilized
basement membrane preparation originally extracted
from a mouse sarcoma; it contains extracellular matrix
proteins, such as laminin and collagen, and growth
factors.
7,8
Radiation
Nude rats received a single dose of 500 cGy total-
body irradiation which was administered using a
cobalt-60 source (Eldorado-8 teletherapy machine,
Atomic Energy of Canada, Ltd.) delivering
approximately 57 cGy/min. During irradiation, awake
rats were placed in a mouse microisolator cage and
covered with a 1¤ 4-inch solid Lucite platform
constructed to ® t the inner cage dimensions and
minimally contact the dorsal surface of the rats. The
rats were used in tumor implantation experiments 4
days after irradiation.
Tumor implantation
Rats were anesthetized using Metophane (Mallinck-
rodt Veterinary, Mundelein, IL) in an inhalation anes-
thetic chamber. The skin over the implantation site
was wiped clean with 70% ethanol. For injection,
200 m l of SKLMS-1 cell suspension containing 10 3
10
6 cells was inoculated into the subcutaneous tissue
in the rat ¯ ank or hind leg using a tuberculin syringe
with a 28-Ga needle (Becton-Dickinson). For
implantation, a 5-mm incision was made in the skin
overlying the ¯ ank or leg, and a single 3 3 2-mm
sliver of tumor tissue was delivered through the inci-
sion site using a trocar and deposited 1 cm away in
the subcutaneous tissue.The skin was closed using a
single wound clip (Becton-Dickinson).
Results
The goal of these experiments was to establish a
method of tumor implantation that would lead to
consistent and reliable human sarcoma xenografts in
the rat ¯ ank and leg. The results of the experiments
are summarized in Table 1. The initial experiments
were conducted using eight NCI nude rats which
were either 9 weeks old (n=5) or 12 weeks old (n=3).
All rats were subcutaneously inoculated at each injec-
tion site with a 200-m l suspension of 10 3 10
6
Table 1. Tumor takes rates achieved with various modi® cations in xenotransplantion method
Rat strain and vendor
Quantity and
age of rats TBI
Tumor cell
preparation Inoculation site
Tumor take/site (%)
at 4 weeks PI
Cr:NIH-RNU; NCI n=5; 9 weeks No Cell suspension 1 ¯ ank and 1 leg/rat Leg 1/5 (20%)
Flank 3/5 (60%)
All sites 4/10 (40%)
Cr:NIH-RNU; NCI n=3; 12 weeks No Cell suspension 1 ¯ ank and 1 leg/rat Leg 0/3 (0%)
Flank 0/3 (0%)
All sites 0/6 (0%)
HSD:rnu/rnu; HSD n=10; 7 weeks 500 rad Tumor sliver +
Matrigel
n=6: 2 ¯ anks and 2
legs/rat
n=4: 1 ¯ ank and 2
legs/rat
Leg 20/20 (100%)
Flank 16/16 (100%)
All sites 36/36 (100%)
HSD:rnu/rnu; HSD n=6; 12 weeks 500 rad Tumor sliver +
Matrigel
2 legs/rat Leg 12/12 (100%)
HSD:rnu/rnu; HSD n=2; 9 weeks 500 rad Cell suspension
+ Matrigel
2 ¯ anks/rat Flank 4/4 (100%)
PI, post-implantation.
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injection sites per rat, the ¯ ank and hind limb, and
these were inspected daily by visual examination and
palpation for evidence of tumor growth. In the group
of rats inoculated at 9 weeks of age, one rat developed
a small tumor nodule (5 mm) in the leg 2 weeks
post-injection; no rat had evidence of tumor growth
in the ¯ ank. At 3 weeks post-injection, two rats had
tumor nodules in the leg and another two in the
¯ ank. At both 4 and 12 weeks post-injection, only
one rat retained a growing tumor nodule in the leg;
the nodule in the other rat had spontaneously
regressed.Three rats had tumor nodules in the ¯ ank.
Maximum tumor nodule diameter at 12 weeks was
1.5 cm.At no time did any of the three rats inoculated
at 12 weeks of age exhibit tumor growth at any site.
For the younger rats, therefore, the overall tumor
take rate for all sites by 12 weeks was four of 10
(40%) and respective values for the leg and ¯ ank
speci® cally were one of ® ve (20%) and three of ® ve
(60%).
The tumor take rates observed with injection of
SKLMS-1 cells in PBS were unsuitable for studies
that require many rats and timely development of
tumor nodules. To optimize the success of
xenografting these sarcoma cells, we modi® ed the
above implantation procedure by using younger rats
(5± 7 weeks old) from a different supplier (Harlan
Sprague± Dawley), treating them with 500 cGy total-
body irradiation to achieve further immunosuppres-
sion, adding M atrigel to the tumor, and
transplanting tumor fragments harvested from a
donor rat. Although each of these changes individu-
ally elicited some improvement (data not shown),
the best results were achieved when all modi® ca-
tions were applied.
Four days after irradiating a group of 10 7-week-old
rats, SKLMS-1 tumor in 3 3 2-mm slivers coated
with Matrigel was implanted subcutaneously in either
three sites or four sites per rat to yield 36 total inocula-
tion sites. Six rats were inoculated in both ¯ anks and
both legs; four rats were inoculated in one ¯ ank and
both legs. No radiation-related adverse effects, such
as skin changes or lethargy, were noted. Eight days
after implantation, tumor nodules were easily palpable
at all sites, and all grew to a diameter of 1 cm by 2
weeks post-implantation (Fig. 1). The tumor take
rate per site with this method was 36/36 (100%). A
similar time course of tumor growth and the same
xenotransplantation rate was achieved in slightly older
rats who were also irradiated at 12 weeks of age. In
this group of rats, tumor nodule formation occurred
at 12/12 sites (100%). Furthermore, two Harlan
Sprague± Dawley rats were irradiated at 7± 9 weeks of
age and injected subcutaneously in both ¯ anks with
SKLMS-1 cells suspended in Matrigel (200 m l
containing 10 3 10
6 cells). Approximately 5 weeks
after injection, 1-cm nodules were palpable at all four
sites and exhibited continued growth.
Discussion
The use of human xenografts in laboratory animals is
an essential component of preclinical cancer therapy
investigations. Xenografts of human tumors are most
commonly modeled in nude mice,
4 whose small size
is convenient for most experimental applications but
limits the investigation of more complex surgical
procedures. For these kinds of studies, the nude rat is
more appropriate. The nude rat has an autosomal
recessive mutation which results in the lack of a
functional thymus.
9T lymphocytes and cell-mediated
immunity are markedly reduced, and xenograft rejec-
tion is diminished or delayed.
9 Because of their larger
size, nude rats permit easier performance of surgical
manipulations, especially on small structures such as
blood vessels. The primary disadvantage of the nude
rats is their relative immune competence compared
to athymic nude mice. Many human tumor xenografts
in nude rats show either greatly diminished tumor
take rates compared to those in nude mice or
spontaneous regression of the tumors.
10± 16 Selected
interventions, such as whole-body irradiation, have
been reported to improve tumor take rates for human
lung cancer models in nude rats.
17,18
The purpose of these experiments was to identify
components of tumor implantation technique that
would lead to consistent and reliable human sarcoma
xenografts in the rat ¯ ank and leg, sites important for
sarcoma research applications. Particularly necessary
was the establishment of similarly sized tumor nodules
growing at a predictable rate in rat limbs intended to
undergo ILP with biochemotherapeutic agents. In
the process of trying to establish this xenograft
method, we observed highly variable tumor take rates
and tumor growth properties. Such variability does
not seem to affect syngeneic rat sarcoma transplants,
which lead to tumor establishment within about 1
week.
19,20 A method of direct tumor implantation
used with a syngeneic rat ® brosarcoma for successful
ILP studies with genetic therapy
21 did not result in
consistent tumor take rates when applied to the
human SKLMS-1 leiomyosarcoma tumor. This
circumstance allowed us to identify several factors
that appear to be important in determining xenograft
tumor take rates. These include the vendor source,
strain and age of rat, presence or absence of whole-
body irradiation, form of transplanted tumor cells
(solid fragment of tumor tissue versus cell suspen-
sion), and presence or absence of a xenograft environ-
ment enriched with growth factors.
The need for these modifcations re¯ ects varying
degrees of immune competency of nude rats, the
malignant phenotype of the particular tumor, and
the importance of local tumor growth factors in
establishing xenografts. The immunological
characteristics of nude rats may vary depending on
the rats’ source and strain.
9 Maximum immunosup-
pression may require changing rat strains or vendor
sources, using younger rats (£ 11 weeks old), and
Human sarcoma xenografts 131further lymphocyte depletion of the selected rats
through whole-body irradiation.The inherent aggres-
siveness of a human tumor may dictate how many of
these modi® cations are needed to ensure xenograft
establishment. Total-body irradiation alone was
sufficient in some lung cancer models.
17,18,20
Manipulation of the xenograft environment may also
improve tumor take rates. Implantation of an
established tumor fragment harvested from a donor
rat may enhance intercellular interactions in a new
host, compared to inoculation of a loose suspension
of cultured tumor cells.
22,23 The cellular environ-
ment may be further enhanced by exogenous growth
factors. Matrigel is a solubilized basement membrane
preparation.We found that the administration of the
tumor fragments in conjunction with Matrigel, which
contains extracellular matrix proteins and growth
factors,
7,8 resulted in optimum tumor take rates and
growth pattern consistency in our sarcoma model.
In summary, we have reported a method of
producing human sarcoma xenografts in the leg of
the nude rat, using a human leiomyosarcoma cell
line, which yields excellent tumor take rates and
consistent, reliable growth patterns.The use of young
nude rats of a select strain, combined with the
administration of 500 cGy whole-body irradiation and
Fig. 1. (A) Nude rat with a human leiomyosarcoma nodule growing in the medial aspect of its lower limb.The rat underwent 500 cGy
total-body irradiation 4 days prior to implantation of a 3 3 2-mm fragment of SKLMS-1 tumor embedded in Matrigel.The tumor reached
1 cm in size by 2 weeks, and consisted of viable heterogeneous cells with appearance consistent with human leiomyosarcomas (b).
132 P.T.Tinkey et al.the use of Matrigel-soaked tumor implants, resulted in
high tumor take rates with no tumor nodule regression
over time. This makes it possible to continue the
investigation of such therapeutic agents as
chemotherapy drugs or gene therapy constructs, and
also brings to attention aspects of xenografting
technique that may be modi® ed to improve tumor take
rates of other human tumor xenografts in nude rats.
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